Economic evaluation plan of a RCT of hydroxyapatite-coated uncemented hemiarthroplasty versus cemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures: the WHiTE5 trial.

This paper describes the methods applied to assess the cost-effectiveness of cemented versus uncemented hemiarthroplasty among hip fracture patients in the World Hip Trauma Evaluation Five (WHiTE5) trial. A within-trial cost-utility analysis (CUA) will be conducted at four months postinjury from a health system (National Health Service and personal social services) perspective. Resource use pertaining to healthcare utilization (i.e. inpatient care, physiotherapy, social care, and home adaptations), and utility measures (quality-adjusted life years) will be collected at one and four months (primary outcome endpoint) postinjury; only treatment of complications will be captured at 12 months. Sensitivity analysis will be conducted to assess the robustness of the results. The planned analysis strategy described here records our intent to conduct a within-trial CUA alongside the WHiTE5 trial.

Informations de copyright

© 2020 Author(s) et al.

Déclaration de conflit d'intérêts

ICMJE COI statement: X. Griffin is funded by a National Institute for Health Research Clinician Scientist Grant. Further funding from industry and charitable grants are and have been made available to his institution (University of Oxford. All decisions relating to the design, conduct, analysis, write-up, and publication of research are independent of these funders. He has ongoing expert consultancy with several companies; none involve the development of any implant for use in hip fracture care. M. L. Costa is a National Institute for Health Research (NIHR) senior investigator and reports payments for ongoing expert consultancy with several companies, none of which involve the development of any implant for use in hip fracture care.